Biotechnology
STAT+: Biosplice, once the most valuable biotech startup, sees a pair of osteoarthritis trials fail
Biosplice’s bid to transform the treatment of everything from arthritis to cancer ran into a snag this week, with the San Diego biotech announcing that its experimental osteoarthritis drug failed to benefit patients in a […]
